Clindamycin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1970
- First approval year
- 1970
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Clindamycin
- Molecular weight
- 424.99
- Structure (SMILES)
- CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1
- 7 s chloro 7 deoxylincomycin
- 7(s)-chloro-7-deoxylincomycin
- chlorodeoxylincomycin
- Chlorodeoxylincomycin
- chlorolincomycin
- Chlorolincomycin
- clindamicina
- Clindamicina
- clindamycin
- Clindamycin
- CLINDAMYCIN [GREEN BOOK]
- CLINDAMYCIN [HSDB]
- clindamycin [INN]
- CLINDAMYCIN [MART.]
- CLINDAMYCIN [MI]
- CLINDAMYCIN [USAN]
- CLINDAMYCIN [VANDF]
- Clindamycin [WHO-DD]
- clindamycin green book
- clindamycin hsdb
- clindamycin inn
- clindamycin mart
- clindamycin mi
- CLINDAMYCIN PHOSPHATE IMPURITY E [EP IMPURITY]
- clindamycin phosphate impurity e ep impurity
And 13 more, listed on the interactive page.
- CAS registry numbers
- 18323-44-9
- ChEMBL ID
- CHEMBL1753
- InChIKey
- KDLRVYVGXIQJDK-AWPVFWJPSA-N
- PubChem compound IDs
- 446598
- FDA ingredient codes (UNII)
- 3U02EL437C
- D10AF01
- G01AA10
- J01FF01
Sources for recorded values
- 2582
- 21235
- Applicant
- PFIZER
- Approval date
- 22 Feb 1970
- Application number
- NDA050162
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- clindamycin
- Type
- Synthetic organic
- Drug name stem
- -mycin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Open Targets mechanisms
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Intraabdominal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D059413
- Condition
- Skin Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Osteomyelitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pain
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Vaginosis, Bacterial
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003932
- Subject identifier
- D016585
- Condition
- Kidney Calculi
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004253
- Subject identifier
- D007669
- Condition
- Staphylococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005681
- Subject identifier
- D013203
- Condition
- Pneumonia, Pneumocystis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007448
- Subject identifier
- D011020
- Condition
- Candidiasis, Vulvovaginal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007543
- Subject identifier
- D002181
- Condition
- Prediabetic State
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001121
- Subject identifier
- D011236
- Condition
- Endometritis
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001312
- Subject identifier
- D004716
- Condition
- Periapical Periodontitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001391
- Subject identifier
- D010485
- Condition
- Hernia, Ventral
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001866
- Subject identifier
- D006555
- Condition
- Nasal Obstruction
- Highest recorded phase
- 3
- Condition identifier
- HP:0001742
- Subject identifier
- D015508
- Condition
- Chorioretinitis
- Highest recorded phase
- 3
- Condition identifier
- HP:0012424
- Subject identifier
- D002825
- Condition
- Hernia
- Highest recorded phase
- 3
- Condition identifier
- HP:0100790
- Subject identifier
- D006547
- Condition
- Sepsis
- Highest recorded phase
- 1
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Vaginitis
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0002234
- Subject identifier
- D014627
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003869
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0003932
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005757
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007429
- Condition identifier
- EFO_0009948
- Condition identifier
- EFO_1000710
- Condition identifier
- EFO_1001121
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001305
- Condition identifier
- EFO_1001312
- Condition identifier
- EFO_1001391
- Condition identifier
- EFO_1001849
- Condition identifier
- HP_0000689
- Condition identifier
- HP_0000789
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 1
- Condition identifier
- HP_0001742
- Highest recorded phase
- 3
- Condition identifier
- HP_0010447
- Condition identifier
- HP_0012531
- Condition identifier
- HP_0031292
- Highest recorded phase
- 2
And 31 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- infectious disease
- Warning
- Black Box Warning
- Effect
- misuse
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- infectious disease
- Country
- United States
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Event
- acute generalised exanthematous pustulosis
- Reports
- 195
- Reporting signal score
- 516.58
- Event
- acute kidney injury
- Reports
- 192
- Reporting signal score
- 83.0635
- Event
- clostridium difficile colitis
- Reports
- 103
- Reporting signal score
- 213.121
- Event
- clostridium difficile infection
- Reports
- 128
- Reporting signal score
- 239.657
- Event
- dermatitis allergic
- Reports
- 99
- Reporting signal score
- 190.933
- Event
- drug hypersensitivity
- Reports
- 1,769
- Reporting signal score
- 3,577.71
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 137
- Reporting signal score
- 178.545
- Event
- fatigue
- Reports
- 75
- Reporting signal score
- 76.4965
- Event
- graft infection
- Reports
- 33
- Reporting signal score
- 139.937
- Event
- oesophageal ulcer
- Reports
- 42
- Reporting signal score
- 86.9612
- Event
- pseudomembranous colitis
- Reports
- 36
- Reporting signal score
- 88.5782
- Event
- rash
- Reports
- 437
- Reporting signal score
- 169.102
- Event
- rash maculo-papular
- Reports
- 211
- Reporting signal score
- 386.663
- Event
- toxic skin eruption
- Reports
- 78
- Reporting signal score
- 124.926
- Event
- type iv hypersensitivity reaction
- Reports
- 99
- Reporting signal score
- 304.007
- Event
- urticaria
- Reports
- 196
- Reporting signal score
- 86.3606
- NCT00000640
- NCT00214643
- NCT00217451
- NCT01361269
- NCT01374581
- NCT01464138
- NCT00219570
- NCT00377000
- NCT00663286
- NCT00664248
- NCT00671749
- NCT00689117
- NCT00713609
- NCT00776919
- NCT00837213
- NCT00838812
- NCT00841776
- NCT00887484
- NCT00891982
- NCT00926367
- NCT00964366
- NCT01015638
- NCT01016977
- NCT01047189
- NCT01132443
And 51 more, listed on the interactive page.
- Dose
- 150 to 300 mg (adults), 8-16 mg/kg/day (children for serious infections), 16-20 mg/kg/day (more severe infections)
- Route
- Oral
- How often
- Every 6 hours
- Administer with a full glass of water
- At least 30 minutes before lying down
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 4
- Polar surface area
- 102.26
- Calculated partition coefficient (ALogP)
- 0.39
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 27
- Molecular formula
- C18H33ClN2O5S
- Monoisotopic mass
- 424.1798710
- Natural product
- Yes
- 0143-9267
- 0143-9268
- 0143-9269
- 0781-3288
- 0781-3289
- 0781-3290
- 72572-074
- 72572-076
- Recorded assays
- 4,097
- Active assays
- 70
- Confirmatory
- Other
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
Related records
Trials (124)
- A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
- A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
- A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
- A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS
- A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
- A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting
- A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
- A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
- A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
- A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris
- A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
- Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
- Adjunctive Clindamycin for Cellulitis: C4C Trial.
- Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
- Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
- An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures
- Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients
- Antibiotic Prophylaxis for Simple Hand Lacerations
- Antibiotic Safety (SCAMP)
Approved for (4)
- Acne
- Bacterial infectious disease
- Endometritis
- Osteomyelitis
In development for (22)
- Abscess Phase 2
- Bacterial vaginosis Phase 3
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Candidiasis Phase 3
- Cellulitis Phase 2
- Chorioretinitis Phase 3
- COVID-19 Phase 2
- Hypertensive disorder Phase 1
- Malaria Phase 3
- Mediastinitis Phase 2
- Nephrolithiasis Phase 3
- Non-small cell lung carcinoma Phase 2
- Periapical periodontitis Phase 2
- Periodontitis Phase 3
- Pneumocystosis Phase 3
- Prediabetes syndrome Phase 2
- Skin disorder Phase 3
- Staphylococcus aureus infection Phase 3
- Type 2 diabetes mellitus Phase 3
Other linked conditions (10)
- Acute tonsillitis
- AIDS
- Anal fistula
- Appendicitis
- Empyema
- Hidradenitis suppurativa
- Meningitis
- Methicillin-resistant staphylococcus aureus infectious disease
- Peritonsillar abscess
- Staphylococcal infection